Rapport Therapeutics Inc (RAPP)

Apr 30, 2026

Rapport Therapeutics Insiders Added US$1.61m Of Stock To Their Holdings - Yahoo Finance

Apr 30, 2026

Apr 30, 2026

Rapport Therapeutics (RAPP) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

Apr 30, 2026

Apr 29, 2026

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat

Apr 29, 2026

Apr 29, 2026

Third Rock Ventures Sells 17 Million Dollars in Rapport Therapeutics - HarianBasis.co

Apr 29, 2026

Apr 28, 2026

Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near - AOL.com

Apr 28, 2026

Apr 28, 2026

Bullish Rapport Therapeutics Insiders Loaded Up On US$1.61m Of Stock - 富途牛牛

Apr 28, 2026

Apr 27, 2026

All you need to know about Rapport Therapeutics, Inc. (RAPP) rating upgrade to buy - MSN

Apr 27, 2026

Apr 26, 2026

Price-Driven Insight from (RAPP) for Rule-Based Strategy - Stock Traders Daily

Apr 26, 2026

Apr 25, 2026

Rapport Therapeutics prices $250M stock at $26 per share - MSN

Apr 25, 2026

Apr 24, 2026

RAPP Should I Buy - Intellectia AI

Apr 24, 2026

Apr 23, 2026

Rapport Therapeutics, Inc. ($RAPP) CEO 2025 Pay Revealed - Quiver Quantitative

Apr 23, 2026

Apr 23, 2026

BTIG Research Reaffirms "Buy" Rating for Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat

Apr 23, 2026

Apr 23, 2026

Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), Danaher (DHR) and Intuitive Surgical (ISRG) - The Globe and Mail

Apr 23, 2026

Apr 23, 2026

Rapport Therapeutics (RAPP) outlines 2026 vote, board structure and executive pay - Stock Titan

Apr 23, 2026

Apr 23, 2026

Rapport Therapeutics Reports Sustained Seizure Reduction With RAP-219 in Phase 2a Focal Onset Seizure Trial at 2026 AAN Meeting - Minichart

Apr 23, 2026

Apr 22, 2026

Rapport Therapeutics advances RAP-219 after strong Phase 2a data - The Globe and Mail

Apr 22, 2026

Apr 22, 2026

Wells Fargo Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $46 - Moomoo

Apr 22, 2026

Apr 22, 2026

Rapport Therapeutics CDO Yeleswaram Krishnaswamy sells $808,844 stock By Investing.com - Investing.com India

Apr 22, 2026

Apr 21, 2026

Third Rock Ventures sells $17.1m in Rapport Therapeutics stock - Investing.com UK

Apr 21, 2026

Apr 21, 2026

Rapport Therapeutics reports extended efficacy data for RAP-219 By Investing.com - Investing.com Australia

Apr 21, 2026

Apr 21, 2026

Insider Sell: Krishnaswamy Yeleswaram Sells Shares of Rapport Th - GuruFocus

Apr 21, 2026

Apr 21, 2026

Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Major Shareholder Sells 426,005 Shares of Stock - MarketBeat

Apr 21, 2026

Apr 21, 2026

Third Rock Ventures sells $17.1m in Rapport Therapeutics stock By Investing.com - Investing.com South Africa

Apr 21, 2026

Apr 21, 2026

RAPP Reports Positive Results from Phase 2a Trial Follow-Up - GuruFocus

Apr 21, 2026

Apr 21, 2026

Krishnaswamy Yeleswaram Sells 20,225 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat

Apr 21, 2026

Apr 21, 2026

Rapport Therapeutics Presents Rap-219 Focal Onset Seizure Phase 2A Follow-Up Period Results - TradingView

Apr 21, 2026

Apr 21, 2026

Rapport Therapeutics CDO Yeleswaram Krishnaswamy sells $808,844 stock - Investing.com

Apr 21, 2026

Apr 21, 2026

Rapport Therapeutics reports extended efficacy data for RAP-219 - Investing.com

Apr 21, 2026

Apr 21, 2026

Rapport Therapeutics reports sustained seizure reductions, 22-day half-life for RAP-219 in Phase 2a follow-up - TradingView

Apr 21, 2026

Apr 21, 2026

Rapport Therapeutics (RAPP) posts durable RAP-219 seizure cuts and details late-stage plans - Stock Titan

Apr 21, 2026

Apr 21, 2026

Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting - The Manila Times

Apr 21, 2026

Apr 20, 2026

Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 4.2%Here's What Happened - MarketBeat

Apr 20, 2026

Apr 20, 2026

Rapport Therapeutics (RAPP) Stock Value Opportunity (On the Radar) 2026-04-20Social Momentum Signals - Xã Vĩnh Công

Apr 20, 2026

Apr 19, 2026

Is Rapport Therapeutics (RAPP) stock continuing its trend (Ticks Higher) 2026-04-18Public Sentiment - Xã Châu Thành

Apr 19, 2026

Apr 17, 2026

Rapport Therapeutics (NASDAQ:RAPP) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat

Apr 17, 2026

Apr 17, 2026

Brokered 10b5-1 sales listed for RAPP (NASDAQ: RAPP) - Stock Titan

Apr 17, 2026

Apr 17, 2026

[144] Rapport Therapeutics, Inc. SEC Filing - Stock Titan

Apr 17, 2026

Apr 15, 2026

(RAPP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Apr 15, 2026

Apr 14, 2026

Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells 9,165 Shares of Stock - MarketBeat

Apr 14, 2026

Apr 14, 2026

Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 500 Shares - MarketBeat

Apr 14, 2026

Apr 14, 2026

Rapport Therapeutics Insider Sold Shares Worth $695,823, According to a Recent SEC Filing - marketscreener.com

Apr 14, 2026

Apr 14, 2026

Rapport Therapeutics (RAPP) CDO sells 19,865 shares under 10b5-1 plan - Stock Titan

Apr 14, 2026

Apr 13, 2026

10b5-1 insider sales reported for RAPP (NASDAQ: RAPP) in March–April 2026 - Stock Titan

Apr 13, 2026

Apr 13, 2026

What is the dividend outlook for Rapport Therapeutics (RAPP) Stock | Price at $34.13, Down 0.12%Expert Entry Points - Newser

Apr 13, 2026

Apr 11, 2026

Is Rapport Therapeutics Inc undervalued by DCF analysis2026 Pullbacks & Reliable Price Breakout Alerts - baoquankhu1.vn

Apr 11, 2026

Apr 11, 2026

How Investors May Respond To Rapport Therapeutics (RAPP) Phase 2a RAP-219 Data Spotlight At AAN 2026 - simplywall.st

Apr 11, 2026